Cascade genetic testing: an underutilized pathway to equitable cancer care?
- 15 May 2024
- journal article
- review article
- Published by Springer Nature in Familial Cancer
- Vol. 23 (2) , 141-145
Abstract
The Precision Medicine Initiative was launched upon the potential of genomic information to tailor medical care. Cascade genetic testing represents a powerful application of precision medicine and involves the process of familial diffusion or the “cascade” of genomic risk information. When an individual (proband) is found to carry a cancer-associated germline pathogenic mutation, the information should be cascaded or shared with at-risk relatives. First degree relatives have a 50% likelihood of carrying the same cancer-associated mutation. This process of cascade testing offers at-risk relatives the opportunity for genetic testing and, for those who also carry the cancer-associated mutation, genetically targeted primary disease prevention through intensive cancer surveillance, chemoprevention and risk-reducing surgery, reducing morbidity and preventing mortality. Cascade testing has been designated by the Centers for Disease Control and Prevention as a Tier 1 genomic application for hereditary breast and ovarian cancer. In this manuscript we describe a cascade genetic testing and in particular focus on its potential to provide necessary care to medically underserved and vulnerable populations.Keywords
Funding Information
- The National Institutes of Health National Cancer Institute (P30 CA016672, P30 CA016672, UG1 CA233330, KL2-TR-002385, P30 CA016672, P30 CA016672)
- National Institutes of Health National Cancer Institute (K08 CA234333)
This publication has 31 references indexed in Scilit:
- Underrepresentation of racial and ethnic minorities in cascade testing for hereditary cancer syndromesEuropean Journal of Human Genetics, 2023
- Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysisGynecologic Oncology, 2021
- Disparities in gynecologic cancer genetics evaluationGynecologic Oncology, 2019
- Disparities in genetics assessment for women with ovarian cancer: Can we do better?Gynecologic Oncology, 2018
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Outcomes of a randomised controlled trial of a complex genetic counselling intervention to improve family communicationEuropean Journal of Human Genetics, 2015
- Family Communication of BRCA1/2 Results and Family Uptake of BRCA1/2 Testing in a Diverse Population of BRCA1/2 CarriersJournal of Genetic Counseling, 2013
- Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch SyndromeJAMA, 2011
- Efficacy of Annual Colonoscopic Surveillance in Individuals With Hereditary Nonpolyposis Colorectal CancerClinical Gastroenterology and Hepatology, 2010
- Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of OnsetGastroenterology, 2005